The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
1206963110 12069631 10 F 20140725 20160719 20160211 20160721 EXP CA-ROCHE-1405402 ROCHE 41.53 YR M Y 60.50000 KG 20160721 MD CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
1206963110 12069631 1 PS AVASTIN BEVACIZUMAB 1 Intravenous (not otherwise specified) N3676B01,N3667B01,N3693,N3699,N3734 125085 450 MG
1206963110 12069631 2 SS AVASTIN BEVACIZUMAB 1 Intravenous (not otherwise specified) N3676B01,N3667B01,N3693,N3699,N3734 125085 420 MG QOW
1206963110 12069631 3 SS AVASTIN BEVACIZUMAB 1 Intravenous (not otherwise specified) N3676B01,N3667B01,N3693,N3699,N3734 125085 510 MG Q3W
1206963110 12069631 4 SS AVASTIN BEVACIZUMAB 1 Intravenous (not otherwise specified) N3676B01,N3667B01,N3693,N3699,N3734 125085 503 MG INFUSION /wk
1206963110 12069631 5 SS AVASTIN BEVACIZUMAB 1 Intravenous (not otherwise specified) N3676B01,N3667B01,N3693,N3699,N3734 125085 488 MG INFUSION /wk
1206963110 12069631 6 SS BENADRYL DIPHENHYDRAMINE HYDROCHLORIDE 1 Oral U 0 50 MG
1206963110 12069631 7 SS SOLU-MEDROL METHYLPREDNISOLONE SODIUM SUCCINATE 1 Intravenous (not otherwise specified) U 0 100 MG
1206963110 12069631 8 C KEPPRA LEVETIRACETAM 1 0
1206963110 12069631 9 C DECADRON DEXAMETHASONE 1 0
1206963110 12069631 10 C PROCHLORAZINE 2 0
1206963110 12069631 11 C TYLENOL ACETAMINOPHEN 1 Oral 0 650 MG
1206963110 12069631 12 C PANTOLOC PANTOPRAZOLE SODIUM 1 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
1206963110 12069631 1 Glioblastoma
1206963110 12069631 6 Product used for unknown indication
1206963110 12069631 7 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
1206963110 12069631 OT
1206963110 12069631 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
1206963110 12069631 Abdominal pain
1206963110 12069631 Alanine aminotransferase increased
1206963110 12069631 Aspartate aminotransferase increased
1206963110 12069631 Bilirubin conjugated increased
1206963110 12069631 Blood albumin decreased
1206963110 12069631 Blood alkaline phosphatase increased
1206963110 12069631 Blood bilirubin increased
1206963110 12069631 Blood chloride increased
1206963110 12069631 Blood creatinine decreased
1206963110 12069631 Blood glucose increased
1206963110 12069631 Blood lactate dehydrogenase increased
1206963110 12069631 Blood pressure increased
1206963110 12069631 Blood sodium increased
1206963110 12069631 Blood testosterone decreased
1206963110 12069631 Blood urea increased
1206963110 12069631 Carcinoembryonic antigen increased
1206963110 12069631 Constipation
1206963110 12069631 Decreased appetite
1206963110 12069631 Dizziness
1206963110 12069631 Dyskinesia
1206963110 12069631 Fatigue
1206963110 12069631 Gait disturbance
1206963110 12069631 Grip strength decreased
1206963110 12069631 Haematocrit decreased
1206963110 12069631 Haemoglobin decreased
1206963110 12069631 Heart rate decreased
1206963110 12069631 Hepatic enzyme increased
1206963110 12069631 Hyperglycaemia
1206963110 12069631 Hypoaesthesia
1206963110 12069631 Immobile
1206963110 12069631 Increased upper airway secretion
1206963110 12069631 Lipase increased
1206963110 12069631 Lymphocyte count decreased
1206963110 12069631 Mean cell haemoglobin increased
1206963110 12069631 Mean cell volume increased
1206963110 12069631 Medication error
1206963110 12069631 Micturition urgency
1206963110 12069631 Mobility decreased
1206963110 12069631 Movement disorder
1206963110 12069631 Nasopharyngitis
1206963110 12069631 Nausea
1206963110 12069631 Neutrophil count increased
1206963110 12069631 Platelet count decreased
1206963110 12069631 Pulpitis dental
1206963110 12069631 Red blood cell count decreased
1206963110 12069631 Red cell distribution width increased
1206963110 12069631 Somnolence
1206963110 12069631 Tooth abscess
1206963110 12069631 Viral infection
1206963110 12069631 Vomiting
1206963110 12069631 Weight decreased
1206963110 12069631 White blood cell count decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
1206963110 12069631 1 20140509 20160427 0
1206963110 12069631 2 20140711 0
1206963110 12069631 3 20141219 0
1206963110 12069631 4 20150501 0
1206963110 12069631 5 20150925 0
1206963110 12069631 6 20140509 20141017 0
1206963110 12069631 7 20140509 0
1206963110 12069631 11 20140509 20141017 0